JP2019536761A5 - - Google Patents

Download PDF

Info

Publication number
JP2019536761A5
JP2019536761A5 JP2019522329A JP2019522329A JP2019536761A5 JP 2019536761 A5 JP2019536761 A5 JP 2019536761A5 JP 2019522329 A JP2019522329 A JP 2019522329A JP 2019522329 A JP2019522329 A JP 2019522329A JP 2019536761 A5 JP2019536761 A5 JP 2019536761A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
composition according
polysorbate
delivery device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536761A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/077793 external-priority patent/WO2018078162A1/en
Publication of JP2019536761A publication Critical patent/JP2019536761A/ja
Publication of JP2019536761A5 publication Critical patent/JP2019536761A5/ja
Priority to JP2022117520A priority Critical patent/JP7473603B2/ja
Pending legal-status Critical Current

Links

JP2019522329A 2016-10-31 2017-10-30 液体医薬組成物 Pending JP2019536761A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022117520A JP7473603B2 (ja) 2016-10-31 2022-07-22 液体医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16196625 2016-10-31
EP16196625.4 2016-10-31
PCT/EP2017/077793 WO2018078162A1 (en) 2016-10-31 2017-10-30 Liquid pharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022117520A Division JP7473603B2 (ja) 2016-10-31 2022-07-22 液体医薬組成物

Publications (2)

Publication Number Publication Date
JP2019536761A JP2019536761A (ja) 2019-12-19
JP2019536761A5 true JP2019536761A5 (enExample) 2020-08-20

Family

ID=57218780

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019522329A Pending JP2019536761A (ja) 2016-10-31 2017-10-30 液体医薬組成物
JP2022117520A Active JP7473603B2 (ja) 2016-10-31 2022-07-22 液体医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022117520A Active JP7473603B2 (ja) 2016-10-31 2022-07-22 液体医薬組成物

Country Status (16)

Country Link
US (2) US11291725B2 (enExample)
EP (2) EP3532029B1 (enExample)
JP (2) JP2019536761A (enExample)
KR (1) KR20190078572A (enExample)
CN (1) CN110062620B (enExample)
AU (1) AU2017351805A1 (enExample)
BR (1) BR112019006853B1 (enExample)
CA (1) CA3040342A1 (enExample)
DK (1) DK3532029T3 (enExample)
ES (1) ES2882181T3 (enExample)
HU (1) HUE054858T2 (enExample)
MY (1) MY192532A (enExample)
RU (1) RU2019116756A (enExample)
SG (1) SG11201902531QA (enExample)
WO (1) WO2018078162A1 (enExample)
ZA (1) ZA201901736B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN110062620B (zh) * 2016-10-31 2023-12-05 德国费森尤斯卡比有限公司 液体药物组合物
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
EP3873437A4 (en) * 2018-10-31 2022-08-03 Richter Gedeon Nyrt. AQUEOUS PHARMACEUTICAL FORMULATIONS
CN115551476A (zh) * 2019-12-10 2022-12-30 米陀科技有限公司 用于线粒体靶向抗氧化剂的不同组合物的聚合物基质
WO2021180821A2 (en) * 2020-03-10 2021-09-16 Tiziana Life Sciences Plc Compositions of il-6/il-6r antibodies and methods of use thereof
ES2987347T3 (es) * 2020-03-13 2024-11-14 Lek Pharmaceuticals Estabilización de composiciones farmacéuticas que comprenden polisorbato
WO2022006051A1 (en) * 2020-06-29 2022-01-06 Anovent Pharmaceutical (U.S.), Llc Formulation of tocilizumab and method for treating covid-19 by inhalation
KR20220028972A (ko) * 2020-08-31 2022-03-08 (주)셀트리온 안정한 약제학적 제제
US20230090654A1 (en) * 2021-08-24 2023-03-23 Homology Medicines, Inc. Adeno-associated virus formulations
JP2025529908A (ja) * 2022-08-26 2025-09-09 アスラン ファーマシューティカルズ ピーティーイー リミテッド 高濃度抗il13r抗体製剤
KR102554775B1 (ko) 2023-02-07 2023-07-12 한국코러스 주식회사 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형
WO2024257040A1 (en) * 2023-06-14 2024-12-19 Enzene Biosciences Limited Composition and stable liquid formulations comprising humanized anti-human interleukin 6 (il-6) receptor monoclonal antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000019I1 (de) 1991-04-25 2009-07-16 Chugai Seiyaku K K 5 1 Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor
EP2311492B1 (en) 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilized preparations
MXPA04007924A (es) 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
JP2009034095A (ja) 2007-07-06 2009-02-19 Sanyo Chem Ind Ltd タンパク質含有水溶液安定化剤、タンパク質含有水溶液の安定化方法及びタンパク質含有水溶液
EP2471510A1 (de) * 2007-08-27 2012-07-04 BioGeneriX AG Flüssigformulierung von G-CSF
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CN104998254A (zh) * 2010-11-08 2015-10-28 基因技术公司 皮下施用的抗-il-6受体抗体
WO2013063510A1 (en) 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
HK1205146A1 (en) * 2012-06-21 2015-12-11 Ucb医药有限公司 Pharmaceutical formulation
CN102961745B (zh) * 2012-09-27 2015-02-18 苏州康聚生物科技有限公司 抗体组合物制剂及其应用
CN110062620B (zh) * 2016-10-31 2023-12-05 德国费森尤斯卡比有限公司 液体药物组合物

Similar Documents

Publication Publication Date Title
JP2019536761A5 (enExample)
JP2019534863A5 (enExample)
JP2022166006A5 (enExample)
Lambros et al. Citric acid: A multifunctional pharmaceutical excipient
RU2019116756A (ru) Жидкая фармацевтическая композиция
JP2015527402A5 (enExample)
ES2540204T3 (es) Formulaciones farmacéuticas de inhibidores de la HDAC
HRP20211417T1 (hr) Formulacije koje stabiliziraju i sprječavaju taloženje imunogenih pripravaka
JP2020138981A5 (enExample)
KR101695580B1 (ko) 증가된 안정성의 신규한 액체 조성물
RU2019112680A (ru) Жидкая фармацевтическая композиция
JP2010513522A5 (enExample)
JP2024001364A5 (enExample)
JP2015535237A5 (enExample)
JP2010522208A5 (enExample)
JP2012526121A5 (enExample)
RU2016150640A (ru) Жидкая фармацевтическая композиция
HRP20250382T1 (hr) Farmaceutski pripravak koji sadrži karbetocin
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
JP2013543843A5 (enExample)
JP2018021007A5 (enExample)
JP2016539921A5 (enExample)
JP2017516847A5 (enExample)
RU2015119603A (ru) Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc
JP2017516848A5 (enExample)